Evidence map›Paper›PMID 34054421›Full record

ReviewFrontiers in neuroscience2021

Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder.

Jiaqi Zhou, Miao Li, Xueying Wang, Yuwen He, Yan Xia, John A Sweeney, Richard F Kopp, Chunyu Liu, Chao Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Pharmaco-Multiomics: A New Frontier in Precision Psychiatry.International journal of molecular sciences · 2025
    Review
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Promises and challenges in pharmacoepigenetics.Cambridge prisms. Precision medicine · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiaqi ZhouCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Miao LiCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xueying WangCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuwen HeCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yan XiaCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
John A SweeneyDepartment of Psychiatry, University of Cincinnati, Cincinnati, OH, United States.
Richard F KoppDepartment of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY, United States.
Chunyu LiuCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chao ChenCenter for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

2/2-Discovery and validation of neuronal enhancers associated with the development of psychiatric disordersU01MH116489 · NIMH · UNIVERSITY OF CHICAGO · PI GAYNOR, SOPHIA, GESCHWIND, DANIEL H · 2018 to 2022
$4.5M
1/2 Measuring translational dynamics and the proteome to identify potential brain biomarkers for psychiatric diseaseR01MH110920 · NIMH · UPSTATE MEDICAL UNIVERSITY · PI LIU, CHUNYU · 2016 to 2019
$2.0M
1/3 High-resolution mapping of cell type-specific DNA (hydroxy)methylation in the human brain during postnatal development and in psychiatric disease.U01MH122591 · NIMH · UPSTATE MEDICAL UNIVERSITY · PI LIU, CHUNYU · 2020 to 2022
$483k
NIMH NIH HHS R01 MH110920NIMH NIH HHS U01 MH116489NIMH NIH HHS U01 MH122591
6 · The paper itself

Abstract

Pharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder (BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved results with limited clinical utility. DNA methylation (DNAm), an epigenetic modification, has been proposed to be involved in both the pathology and drug treatment of these disorders. Emerging data indicates that DNAm could be used as a predictor of drug response for psychiatric disorders. In this study, we performed a systematic review to evaluate the reproducibility of published changes of drug response-related DNAm in SCZ, BD and MDD. A total of 37 publications were included. Since the studies involved patients of different treatment stages, we partitioned them into three groups based on their primary focuses: (1) medication-induced DNAm changes (

Indexed as

bipolar disorderDNA methylationdrug responsemajor depressive disorderpharmacoepigeneticschizophrenia

Identifiers

PMID34054421
PMCPMC8155631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.